Abstract
Testicular cancer represents the most common solid malignancy of young men aged 15–40 years. Germ cell tumors are best divided into those with pure seminoma and non-seminoma histology. The treatment of metastatic testicular germ cell tumors is based on risk stratification according to histological feature, clinical stages and IGCCCG classification. Clinical stage II disease (CS II) is defined by the presence of testicular cancer in the orchiectomy specimen and imaging studies of the abdomen and pelvis that show positive regional lymph nodes. Other potential sites of metastasis, such as the chest, are free of disease. About 10–30 percent of patients with seminoma and non-seminoma have stage CS II disease at clinical presentation. These patients with lymphatic metastasis should be treated with individualized risk-stratification and within a multidisciplinary approach of chemotherapy, radiotherapy and surgery at centres of excellence.
This is a preview of subscription content, log in via an institution to check access.
References
Albers P, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–68.
Andre F, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer. 2000;36(11):1389–94.
Beyer J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24(4):878–88.
Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337(4):242–53.
Chung PW, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol. 2004;45(6):754–9. discussion 759–60
Classen J, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21(6):1101–6.
Culine S, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008;26(3):421–7.
de Wit R, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995;71(6):1311–4.
Decoene J, Winter C, Albers P. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. Urol Oncol. 2015;33(1):23.e15–21.
Fossa SD, et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumors (EORTC trial 30948). Br J Cancer. 2005;93(11):1209–14.
Garcia-del-Muro X, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol. 2008;26(33):5416–21.
Hinz S, et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol. 2008;179(3):936–40, discussion 940
Horwich A, et al. Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol. 2013;24(8):2104–7.
Kollmannsberger C, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011;22(4):808–14.
Krege S, et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol. 2006;17(2):276–80.
Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008a;53(3):478–96.
Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008b;53(3):497–513.
Stephenson AJ, et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol. 2007;25(35):5597–602.
Tandstad T, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol. 2011;29(6):719–25.
Weissbach L, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol. 2000;37(5):582–94.
Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2011;7(1):43–53.
Winter C, et al. Retroperitoneal lymph node dissection after chemotherapy. BJU Int. 2009;104(9 Pt B):1404–12.
Zengerling F, et al. German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. Oncol Rep. 2014;31(6):2477–81.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Winter, C. (2019). Treatment of Clinical Stage II (CS II) Disease in Testicular Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_6-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-42603-7_6-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42603-7
Online ISBN: 978-3-319-42603-7
eBook Packages: Springer Reference MedicineReference Module Medicine